NYSE:GLS

Gelesis Stock Forecast, Price & News

$1.60

-0.09 (-5.33%)

(As of 06/24/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.50
▼
$1.78
50-Day Range: $1.60
▼
$5.35
52-Week Range: $1.50
▼
$12.23

Volume: 804,427 shs
Average Volume: 156,408 shs
Market Capitalization: $115.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

GLS Stock Forecast (MarketRank)

Overall MarketRank^™

0.33 out of 5 stars

Medical Sector

1323rd out of 1,411 stocks

Pharmaceutical Preparations Industry

646th out of 672 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Gelesis.

0.0 Community Rank

Outperform Votes
Gelesis has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Gelesis has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Gelesis and other stocks. Vote “Outperform” if you believe GLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Gelesis does not currently pay a dividend.
Dividend Growth
Gelesis does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gelesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,019.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

About Gelesis (NYSE:GLS)

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

June 21, 2022 | seekingalpha.com

Gelesis announces additional $15M pre-order for Plenity

June 20, 2022 | americanbankingnews.com

Insider Buying: Gelesis Holdings, Inc. (NYSE:GLS) Director Acquires $48,018.75 in Stock

June 5, 2022 | finance.yahoo.com

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

June 4, 2022 | finance.yahoo.com

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

May 28, 2022 | nasdaq.com

Gelesis Holdings, Inc. Common Stock (GLS)

May 27, 2022 | investing.com

Gelesis Holdings Inc (GLS)

May 18, 2022 | finance.yahoo.com

Gelesis to Participate in Upcoming Investor Conferences

May 14, 2022 | seekingalpha.com

Gelesis Holdings' (GLS) CEO Yishai Zohar on Q1 2022 Results - Earnings Call Transcript

May 13, 2022 | seekingalpha.com

Gelesis Holdings GAAP EPS of -$0.70, revenue of $7.51M

May 9, 2022 | finance.yahoo.com

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

May 4, 2022 | finance.yahoo.com

Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes

April 29, 2022 | finance.yahoo.com

Gelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:GLS
CUSIP: N/A
CIK: 1805087
Web: capstarspac.com
Phone: 512-340-7800
Fax: N/A
Employees: 2
Year Founded: N/A

Company Calendar

Last Earnings: 5/12/2022
Today: 6/26/2022
Next Earnings (Estimated): 8/11/2022
Fiscal Year End: 12/31/2022

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12.90 million
Net Margins: N/A
Pretax Margin: -0.73%
Return on Equity: -179.96%
Return on Assets: 15.16%

Debt

Debt-to-Equity Ratio: 3.38
Current Ratio: 1.42
Quick Ratio: 1.10

Sales & Book Value

Annual Sales: $11.19 million
Price / Sales: 10.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.76) per share
Price / Book: -0.21

Miscellaneous

Outstanding Shares: 72,390,000
Free Float: N/A
Market Cap: $115.82 million
Optionable: Not Optionable
Beta: 0.95

Gelesis Frequently Asked Questions

How has Gelesis' stock performed in 2022?: Gelesis' stock was trading at $6.53 at the beginning of 2022. Since then, GLS stock has decreased by 75.5% and is now trading at $1.60.
View the best growth stocks for 2022 here.
When is Gelesis' next earnings date?: Gelesis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Gelesis.
How were Gelesis' earnings last quarter?: Gelesis Holdings, Inc. (NYSE:GLS) issued its earnings results on Thursday, May, 12th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $7.51 million for the quarter.
View Gelesis' earnings history.
What guidance has Gelesis issued on next quarter's earnings?: Gelesis updated its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $58.00 million-$58.00 million.
Who are Gelesis' key executives?: Gelesis' management team includes the following people:
Mr. Yishai Zohar, Founder, Pres, CEO & Director (Age 59, Pay $689.95k)
Mr. Elliot Maltz CPA, CFO & Treasurer (Age 37, Pay $486.26k)
Dr. David Pass Pharm.D., COO & Chief Commercial Officer (Age 53)
Mr. David Abraham J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56, Pay $494.73k)
Dr. Elaine Chiquette Pharm.D., Chief Scientific Officer (Age 55)
Dr. Harry L. Leider FACPE, M.B.A., M.D., MBA, Chief Medical Officer (Age 63)
Ms. Joy Bauer M.S., MS, RDN, Chief Nutrition Officer of Plenity
Who are some of Gelesis' key competitors?: Some companies that are related to Gelesis include Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Altimmune (ALT), Protagonist Therapeutics (PTGX), Imago BioSciences (IMGO), Centessa Pharmaceuticals (CNTA), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), Edgewise Therapeutics (EWTX), Arbutus Biopharma (ABUS), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR), Tango Therapeutics (TNGX) and Aerovate Therapeutics (AVTE).
View all of GLS's competitors.

What is Gelesis' stock symbol?: Gelesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "GLS."
Who are Gelesis' major shareholders?: Gelesis' stock is owned by many different institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (1.61%), Vanguard Group Inc. (1.16%), BlackRock Inc. (0.82%), Beacon Pointe Advisors LLC (0.16%), State Street Corp (0.16%) and Northern Trust Corp (0.11%).
View institutional ownership trends for Gelesis.
Which major investors are buying Gelesis stock?: GLS stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Vanguard Group Inc., BlackRock Inc., Beacon Pointe Advisors LLC, State Street Corp, Northern Trust Corp, Northeast Financial Consultants Inc, and Goldman Sachs Group Inc..
View insider buying and selling activity for Gelesis or or view top insider-buying stocks.
How do I buy shares of Gelesis?: Shares of GLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gelesis' stock price today?: One share of GLS stock can currently be purchased for approximately $1.60.
How much money does Gelesis make?: Gelesis (NYSE:GLS) has a market capitalization of $115.82 million and generates $11.19 million in revenue each year.
How many employees does Gelesis have?: Gelesis employs 2 workers across the globe.
How can I contact Gelesis?: Gelesis' mailing address is 405 WEST 14TH STREET, AUSTIN TX, 78701. The official website for Gelesis is capstarspac.com. The company can be reached via phone at 512-340-7800 or via email at 0.

This page (NYSE:GLS) was last updated on 6/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources